Sarah Sammons: Learning about Leptomeningeal Disease in Breast Cancer
Sarah Sammons, Breast Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared a post on X/Twitter:
“Learning about Leptomeningeal Disease in Breast Cancer this AM! Excellent presentation by Dr. Thomas Grinda. Should we use intrathecal chemotherapy (IT) or systemic chemotherapy or both?
IT chemo in metastatic breast cancer (MBC) has never been shown to improve quality of life, survival in patients. IT Methotrexate is the only drug available in the US with marginal median Breast Cancer efficacy. Newer systemic therapies with CNS efficacy are promising. Not a lot of enthusiasm for IT chemotherapy at Dana-Farber Cancer Institute. Rarely case by case basis.
Very hopeful for Antibody Drug Conjugates (ADCs) efficacy including Trastuzumab deruxtecan (T-DXd) in Leptomeningeal Disease.”
Source: Sarah Sammons/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023